Immune checkpoint inhibitors (ICIs), targeting program death-1 (PD-1) or its ligand (PD-L1), have changed the treatment paradigm of non-small cell lung cancer (NSCLC). This evidence concerns the gene CD274 and non-small cell lung carcinoma.